Collegium Pharmaceutical Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical or view top-rated stocks.

Wall Street analysts have given Collegium Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Collegium Pharmaceutical saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 3,620,000 shares, a drop of 12.1% from the July 29th total of 4,120,000 shares. Based on an average daily trading volume, of 305,200 shares, the short-interest ratio is currently 11.9 days. Approximately 10.5% of the company's stock are sold short.
View Collegium Pharmaceutical's Short Interest.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, August, 5th. The specialty pharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by $0.07. The specialty pharmaceutical company earned $82.94 million during the quarter, compared to the consensus estimate of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a trailing twelve-month return on equity of 22.59%.
View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, COLL shares have increased by 13.7% and is now trading at $19.97.
View which stocks have been most impacted by COVID-19.

Collegium Pharmaceutical updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $335 million-$355 million, compared to the consensus revenue estimate of $346.30 million.

3 brokers have issued 12 month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $32.00. On average, they expect Collegium Pharmaceutical's stock price to reach $27.33 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical or view top-rated stocks among Wall Street analysts.

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Some companies that are related to Collegium Pharmaceutical include Agios Pharmaceuticals (AGIO), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Prestige Consumer Healthcare (PBH), Sage Therapeutics (SAGE), Lyell Immunopharma (LYEL), OPKO Health (OPK), Arcus Biosciences (RCUS), Erasca (ERAS), Pacira BioSciences (PCRX), ATA (ATAI), Verve Therapeutics (VERV), Taro Pharmaceutical Industries (TARO), IGM Biosciences (IGMS) and Atea Pharmaceuticals (AVIR).
View all of COLL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.08%), Vanguard Group Inc. (6.30%), Renaissance Technologies LLC (3.51%), State Street Corp (3.25%), Principal Financial Group Inc. (2.93%) and Invesco Ltd. (2.74%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Rice Hall James & Associates LLC, Citadel Advisors LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Legal & General Group Plc, Bank of America Corp DE, and Susquehanna International Group LLP. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer, and Shirley R Kuhlmann.
View insider buying and selling activity for Collegium Pharmaceutical or view top insider-selling stocks.

COLL stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Dimensional Fund Advisors LP, Massachusetts Financial Services Co. MA, Federated Hermes Inc., Charles Schwab Investment Management Inc., Millennium Management LLC, State Street Corp, and Vanguard Group Inc..
View insider buying and selling activity for Collegium Pharmaceutical or or view top insider-buying stocks.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $19.97.

Collegium Pharmaceutical has a market capitalization of $710.21 million and generates $310.02 million in revenue each year. The specialty pharmaceutical company earns $26.75 million in net income (profit) each year or $0.76 on an earnings per share basis.

Collegium Pharmaceutical employs 234 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical is headquartered at 100 Technology Center Drive, Stoughton MA, 02072.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at (781) 713-3699.